Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

ShedRx vs TOM Weight Loss

Two GLP-1 desks, one scoreboard. We put ShedRx and TOM Weight Loss head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →
vs
No. 64 · Grade C

TOM Weight Loss

Visit TOM Weight Loss Full brief →

The verdict

ShedRx takes this head-to-head.

ShedRx scores 87 to 77 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.

That doesn't make TOM Weight Loss a bad call — it's best for readers who want texas or utah patients wanting direct abom-certified physician access at competitive flat-rate pricing. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
86
78
Supply Reliability
86
75
Transparency
84
88
Access Breadth
85
56
Clinical Oversight
85
91
Track Record
86
73
ShedRxBrief Score 87 · 77TOM Weight Loss

Price, coverage & the tracker

ShedRxTOM Weight Loss
Brief Score87/100 (B+)77/100 (C)
Semaglutide$199/moFrom $199/mo (all doses, compounded)
Tirzepatide$299/moFrom $249/mo (all doses, compounded)
CoverageNot disclosed2 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
On the trackerFallingprice fallingNewnew to the tracker, no prior reading

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

TOM Weight Loss: New to the tracker on 1 August 2026. The published line reads From $199/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.